<DOC>
	<DOCNO>NCT01297959</DOCNO>
	<brief_summary>This study intend determine efficacy topical application E-101 Solution directly surgical incisional wound prevention infection superficial deep surgical incisional wound . E-101 Solution enzyme-based antiseptic developed direct application surgical incision .</brief_summary>
	<brief_title>Efficacy Safety E-101 Solution Preventing Surgical Site Infections After Colorectal Surgery</brief_title>
	<detailed_description>The purpose standard-of-care , pivotal Phase 3 study evaluate efficacy safety topical E-101 Solution direct application principal surgical incision prevention superficial deep incisional surgical site infection ( SSI ) within 30 day elective colorectal surgery . The study intend support target indication statement : `` E-101 Solution indicate prophylaxis incisional surgical site infection follow elective colorectal surgery '' . E-101 Solution comprise active ingredient glucose oxidase ( GO ) porcine myeloperoxidase ( pMPO ) produce couple reaction addition glucose substrate . The hypothesis E-101 Solution topically apply directly principal incision safe significantly reduce incidence incisional SSI compare placebo topical application . ( The principal surgical incision ≥ 5cm &lt; 35 cm use hand port , colorectal specimen extraction port , extracorporeal manipulation port depend specific colorectal surgical approach . )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Scheduled undergo elective colon and/or rectal surgical procedure involve open laparotomy , handassisted laparoscopy , laparoscopicassisted approach . The principal incision must length &gt; 5 cm &lt; 35 cm length . Eligible surgery : leave hemicolectomy , right hemicolectomy , transverse colectomy , ileocolic resection , total abdominal colectomy ileorectal anastomosis , total abdominal proctocolectomy ( portion specimen extract via laparotomy ) , low anterior resection , sigmoid resection , nonemergent Hartmann procedure , colostomy takedown laparotomy ( peristomal ) incision , ileopouch anal anastomosis , abdominal perineal resection rectum . 2 . Able give inform consent . 3 . Male female ≥18 year age . 4 . If female , nonpregnant ( negative pregnancy test result Screening/Randomization Visit ) nonlactating . 5 . If female , either childbearing potential ( define postmenopausal least 1 year surgically sterile [ status post bilateral tubal occlusion , bilateral oophorectomy , hysterectomy ] ) practice 1 follow method birth control agree continue regimen study surveillance period : Oral , implantable , injectable contraceptive 3 consecutive month Baseline/Randomization Visit Intrauterine device Double barrier method ( condom , sponge , diaphragm spermicidal jelly cream ) Not sexuallyactive . Agreement available evaluation study site schedule visit . 1 . Hypersensitivity porcine product . 2 . History known antimyeloperoxidase autoantibody ( i.e. , pANCA ) , well patient know idiopathic necrotizing glomerulonephritis certain systemic vasculitis condition [ e.g. , microscopic polyangiitis small blood vessel , Wegener 's granulomatosis , ChurgStrauss Syndrome ] ) . 3 . Use microbial sealant ( IntegusealTM ) , antibioticembedded suture , antimicrobialembedded suture close principal incision suture surgical field formally approve relevant local national regulatory authority . 4 . Absolute contraindication general anesthesia . 5 . Hypersensitivity reaction steristrip tape , medicalsurgery tape , adhesive , suture . ( Note : If assurance subject expose material cause hypersensitivity , alternative allow . ) 6 . History keloid hypertrophic scar within near incision prior surgery . 7 . Body mass index [ BMI ] : &gt; 50 &lt; 20 ( due extremely high risk poor wound heal ) . 8 . ASA score &gt; 3 . 9 . Undergoing emergency colorectal surgery standard bowel preparation standard preoperative precaution assessment perform time indexsurgery . 10 . The planned indexsurgery involve removal placement mesh ( either synthetic biological ) part closure principal incision traverse part preexist mesh ( either synthetic biological ) principal incision . 11 . There clinical sign overt infection necessitate systemic antibiotic via oral , intramuscular , intravenous route ( e.g. , infection abdominal wall , peritonitis , pneumonia , sepsis/septic shock ) prior indexsurgery . 12 . Preoperative severe neutropenia ( total neutrophil count ≤500 X 109/L ) . ( Note : Testing perform local laboratory . ) 13 . Receiving oral intravenous antibiotic within 24 hour prior indexsurgery . ( Note : It permissible administer conventional oral prophylactic antibiotic bowel preparation time index surgical procedure , well intravenous intramuscular prophylactic antibiotic prior indexsurgery per treat surgeon 's standard care . ) 14 . Preoperative evaluation intraabdominal process might preclude full closure skin incision due severe morbid obesity ( i.e. , mechanical reason would prevent/preclude primary intent wound heal ) principal incision . 15 . History major organ transplantation ( e.g. , lung , liver , kidney ) , include bone marrow transplantation , intent perform major organ transplant concomitant surgery . 16 . History complicate laparotomy within 30 day prior plan indexsurgery . 17 . Planning undergo second colorectal surgical procedure ( e.g. , colostomy ileostomy takedown ) general surgery le 30 day indexsurgery . 18 . Likely preoperative urinary tract infection , evident : ) symptom upper urinary tract infection ( e.g. , fever and/or flank pain ) ii ) symptom low urinary tract infection ( e.g. , urinary frequency , dysuria , urgency , and/or suprapubic pain ) ; accompany one following : 1 ) bacteriuria ≥104 bacteria/mL urine 2 ) positive urine leucocyte esterase positive nitrite urine dipstick test . Also exclude man age 60 year positive urine nitrite leucocyte esterase dipstick test even asymptomatic ( unless predispose factor urinary tract infection e.g. , spinal cord injury ) . ( Note : Testing perform local laboratory . ) 19 . Undergoing significant concomitant surgical procedure ( e.g. , hysterectomy ) mesh repair ( either synthetic biological mesh ) part closure . The following concomitant procedure allow : appendectomy , cholecystectomy , oophorectomy , removal Meckel 's diverticulum , primary repair small ventral hernia ( i.e. , &lt; 30 cm2 ) , liver biopsy/wedge resection ( liver resection ) . 20 . Patients condition ( e.g. , recurrent urinary tract infection , nail infection , sinusitis , dental infection , vaginitis/vaginosis , chronic bronchitis ) require frequent chronic administration antimicrobial ( receive antibiotics/antimicrobials least twice ≥ 2 week past 6 month ) . 21 . Preoperative prothrombin time INR &gt; 2 x upper limit normal . ( Note : Testing perform local laboratory . ) 22 . Postsurgical life expectancy ≤ 60 day ( Investigator 's Sponsor 's opinion ) . 23 . Any patient plan surgery would include : ) placement stoma principal incision ; ii ) placement drain supraperitoneal fascia space emerge principal incision ; iii ) placement drain intraperitoneal space emerge principal incision ; iv ) supplementation irrigation fluid antibiotic antiseptic drug . 24 . Patients severe COPD likely need &gt; 24 hour postoperative ventilator support ( e.g. , patient chronic intermittent supplemental oxygen estimate forced expiratory volume 1 second ( FEV1 ) less 50 % expect base bedside spirometry ) . 25 . If , opinion Investigator , potential subject would likely unable maintain adequate care principal incision postoperatively . 26 . Anticipate patient available study visits/ procedure opinion Investigator concern patient might comply study visits/procedures ( e.g. , due ongoing illicit drug usage alcohol abuse ) . 27 . Lack willingness personal studyrelated data collect , archive , transmit blinded condition regulatory agency . 28 . Participation within 30 day start study experimental drug device study ; currently participate study administration investigational drug device within 60 day anticipate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Surgical Wound Infection</keyword>
	<keyword>Therapeutic Enzyme System</keyword>
	<keyword>Singlet Oxygen</keyword>
	<keyword>Peroxidase</keyword>
	<keyword>Glucose Oxidase</keyword>
	<keyword>Colorectal surgery</keyword>
	<keyword>Incisional Surgical Site Infections ( SSI )</keyword>
	<keyword>Anti-infective Agents , Local</keyword>
	<keyword>Clinical Trial , Phase III</keyword>
</DOC>